SecBot SecBot
SECBOTREPLAY Home › Report › URGN

URGN · UroGen Pharma reported full-year 2025 financial results with total…

UroGen Pharma Ltd. · PRESS-RELEASE filed Mar 2, 2026 at 08:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 2, 2026 at 08:00 ET

UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the commercial launch of ZUSDURI ($15.8M in sales) and 7% underlying growth in JELMYTO sales ($94M). The company refinanced its debt with Pharmakon Advisors for $200M in non-dilutive capital, strengthening its balance sheet. Despite higher R&D and SG&A expenses, management expressed confidence in ZUSDURI's launch trajectory following the January 2026 effective J Code, and provided 2026 JELMYTO sales guidance of $97M–$101M.

  • ZUSDURI achieved $15.8 million in net sales in 2025, its first full year post-FDA approval (June 2025).
  • JELMYTO generated $94.0 million in 2025, reflecting 7% year-over-year underlying demand growth.
  • Total revenue increased 21% YoY to $109.8 million in 2025.
  • Net loss widened to $153.5 million ($3.19/share) in 2025 from $126.9 million ($2.96/share) in 2024.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access